Comparing KalVista Pharmaceuticals (NASDAQ:KALV) & Hillstream BioPharma (NASDAQ:HILS)

KalVista Pharmaceuticals (NASDAQ:KALV) and Hillstream BioPharma (NASDAQ:HILS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Institutional and Insider Ownership

13.4% of Hillstream BioPharma shares are held by institutional investors. 10.5% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 30.2% of Hillstream BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares KalVista Pharmaceuticals and Hillstream BioPharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	N/A	N/A	-$126.64 million	($3.64)	-3.27
Hillstream BioPharma	N/A	N/A	-$8.47 million	($0.72)	-2.11

KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Hillstream BioPharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

KalVista Pharmaceuticals has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Hillstream BioPharma has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500.

Profitability

This table compares KalVista Pharmaceuticals and Hillstream BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-103.92%	-88.06%
Hillstream BioPharma	N/A	-188.44%	-149.61%

Analyst Ratings

This is a breakdown of current ratings and target prices for KalVista Pharmaceuticals and Hillstream BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	0	0	6	1	3.14
Hillstream BioPharma	0	0	0	0	0.00

KalVista Pharmaceuticals presently has a consensus price target of $23.80, suggesting a potential upside of 99.66%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe KalVista Pharmaceuticals is more favorable than Hillstream BioPharma.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

About Hillstream BioPharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.